Assessment of the measurement of canine and feline serum fibroblast growth          factor-23 concentrations by automated chemiluminescence immunoassay

Miyakawa, Hirosumi; Hsu, Huai-Hsun; Ogawa, Mizuki; Miyagawa, Yuichi; Takemura, Naoyuki

doi:10.1292/jvms.21-0566

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the stability of FGF-23 in feline serum samples stored at −20 • C was demonstrated for a storage period of up to 28 days [36] and 14 days [29], the FGF-23 concentrations in our study were likely not affected by storage at −20 • C for a maximum of 5 working days. Although the laboratory recommends taking blood samples in cats that have fasted overnight, it was not possible to collect information regarding the diet and fasting status of the cats included due to the retrospective study design.…”

Section: Discussionmentioning

confidence: 55%

“…Several studies investigating FGF-23 concentration in cats have been performed so far. Different diagnostic quantitative enzyme linked immunosorbent assay (ELISA) kits have been used for this purpose: Four of these studies used the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) [29,31,33,34]; two further studies used MyBioSource ELISA (MyBioSource, San Diego, CA, USA) [30,35]; and in another one, MedFrontier FGF23 ELISA (Minaris Medical Co., Tokyo, Japan) [36] was used. As knowledge regarding the performance of different diagnostic assays for FGF-23 concentration measurements in cats remains limited, the aim of this study was to compare three diagnostic assays for the measurement of FGF-23 concentration and to evaluate the correlation of this parameter with other parameters involved in renal dysfunction in cats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Lapsina,

Nagler,

Müller

et al. 2023

Animals

View full text Add to dashboard Cite

Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aim of this pilot study was to compare three diagnostic assays and to assess how the results correlate with parameters of renal dysfunction in cats. Four groups of 10 cats each were formed retrospectively according to creatinine, based on IRIS staging. FGF-23 was measured using two different ELISAs (MyBioSource and Kainos ELISA FGF-23 Kit) and an automated assay on the DiaSorin Liaison platform. Measurements were performed in 40 cats. Spearman’s rank correlation coefficient showed a strong correlation between the Kainos and DiaSorin assays (ρ = 0.742/p < 0.001) and a low correlation (ρ = 0.443/p = 0.005) between the Kainos and MyBioSource assays. The measurements with the Kainos assay strongly correlated with urea (ρ = 0.835/p < 0.001) and creatinine (ρ = 0.764/p < 0.001), and moderately correlated with SDMA (ρ = 0.580/p < 0.001) and phosphorus (ρ = 0.532/p < 0.001). The results of the MyBioSource and DiaSorin assays only showed a moderate correlation with urea (ρ = 0.624/0.572) and creatinine (ρ = 0.622/0.510) concentrations (p = 0.001 each). The Kainos assay showed the strongest correlation (ρ = 0.806) with the various creatinine concentrations according to the IRIS, followed by the MyBioSource (ρ = 0.663/p < 0.001) and DiaSorin assays (ρ = 0.580/p < 0.001). Overall, the Kainos assay demonstrated the best correlations with both biomarkers and various creatinine concentrations according to the IRIS. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Introductionmentioning

confidence: 99%

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Lapsina,

Nagler,

Müller

et al. 2023

Animals

View full text Add to dashboard Cite

show abstract

“…The CL-Jack assay uses the same antibodies as the MedFrontier assay but has been shown to yield relatively lower concentrations compared with the MedFrontier ELISA at higher FGF-23 concentrations. 42 The IDEXX test suggests measuring an FGF-23 concentration in cats with a diagnosis of stage 1 or 2 CKD to help veterinarians decide which cats may benefit from phosphate reduction therapy. The RI for the assay is <300 pg/ml.…”

Section: Discussionmentioning

confidence: 99%

Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Summers,

Michael,

Szlosek

et al. 2024

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives This study undertook a scoping review of research on blood fibroblast growth factor 23 (FGF-23) concentrations in healthy non-azotemic cats and cats with chronic kidney disease (CKD) to describe the volume and nature of existing literature, to determine whether published studies provide adequate evidence to support the use of FGF-23 as a biomarker in clinical practice and to identify any existing gaps in knowledge. Methods PRISMA Extension for Scoping Reviews guidelines were used to design and perform the scoping review. Online databases were used to identify observational and clinical studies of blood FGF-23 concentrations in healthy cats and cats with CKD published before December 2022. Study and population characteristics and descriptive data on FGF-23 concentrations were extracted. Results A total of 205 publications were reviewed; 17 were retained for inclusion. Most studies were retrospective. Most studies included cats with International Renal Interest Society stage 2–4 CKD, with some variation. Key concepts explored in the literature include FGF-23 concentrations by CKD stage, effect of dietary phosphate restriction on FGF-23 concentrations, relationship between FGF-23 concentrations and blood phosphorus, calcium and magnesium concentrations, and FGF-23 concentrations in cats with progressive CKD. FGF-23 concentrations tended to be higher in cats with CKD compared with healthy cats, with an overlap between healthy and CKD populations, and there was significant variation within stages of CKD. Conclusions and relevance FGF-23 is a biomarker of interest for the management and monitoring of phosphate overload in cats. Studies support several potential clinical applications for measuring FGF-23 concentration in practice; however, evidence is limited. Research on FGF-23 in cats with CKD would benefit from longitudinal, prospective studies that standardize CKD diagnosis and categorize cats by stage using current guidelines. Studies should include cats with early-stage, non-azotemic CKD and use commercially available assays so such results are comparable across studies.

show abstract

“…Regarding the use of available FGF-23 assays in cats, several studies have been performed. The following diagnostic quantitative enzyme-linked immunosorbent assay (ELISA) kits have been tested: the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) by four studies [ 15 , 17 , 19 , 20 ], the MyBioSource ELISA (MyBioSource, San Diego, CA, USA) by two studies [ 16 , 21 ], and the MedFrontier FGF23 ELISA (Minaris Medical Co., Tokyo, Japan) by another study [ 22 ]. In a study from 2023 performed by the same authors, where the FGF-23 ELISA kit, the MyBioSource ELISA, and the LIAISON FGF 23 kit for intact FGF-23 were all compared on the Liaison platform developed by DiaSorin (Saluggia, Italy), the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) demonstrated the best correlation with various creatinine concentrations according to the IRIS [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Lapsina,

von Luckner,

Nagler

et al. 2024

Animals

View full text Add to dashboard Cite

Fibroblast growth factor (FGF)-23 is a phosphaturic hormone. An association between increasing FGF-23 levels and progression of chronic kidney disease (CKD) was documented in cats, dogs, and humans. The information regarding reference intervals (RIs) of FGF-23 in cats is limited. We aimed to establish RIs in a large cohort of clinically healthy cats and to investigate correlations with sex and age. A total of 118 cats with unremarkable complete blood count and serum chemistry profile were included. Clinically sick cats, cats with concurrent diseases, suspicion of CKD, or receiving renal diets were excluded. FGF-23 concentrations were measured with the FGF-23 ELISA Kit. RIs were calculated using the reference interval advisor software 2.1 (Microsoft Excel). FGF-23 concentrations were correlated with sex and age. The RI for FGF-23 concentrations spanned 85.8 to 387.0 pg/mL (90% confidence interval: lower limit 40.5 to 103.9 pg/mL, upper limit: 354.6 to 425.0 pg/mL). No significant relationships (r2 = 0.044) were detected with age (p = 0.081) or sex (p = 0.191). Other studies of the same diagnostic assay calculated RIs of 56 to 700 pg/mL in 79 cats and <336 pg/mL in 108 cats, and in concordance with the present study, did not detect any correlation with sex or age.

show abstract

Assessment of the measurement of canine and feline serum fibroblast growth factor-23 concentrations by automated chemiluminescence immunoassay

Cited by 3 publications

References 12 publications

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Contact Info

Product

Resources

About